Goiter: Drugs That Cause or Treat It

What Is a Goiter and Why Does It Form?

A goiter refers to any abnormal enlargement of the thyroid gland, regardless of whether hormone levels are normal, elevated, or low. The thyroid sits at the base of the neck and produces triiodothyronine (T3) and thyroxine (T4), hormones that regulate metabolism, heart rate, and body temperature. When the gland is overstimulated or structurally altered, it grows.

The World Health Organization estimates that goiter affects approximately 200 million people globally, with iodine deficiency remaining the leading cause in developing nations. In iodine-sufficient countries like the United States, autoimmune thyroid disease (Hashimoto's thyroiditis and Graves' disease) accounts for most cases [1]. Thyroid-stimulating hormone (TSH) from the pituitary gland drives thyroid cell growth when the gland cannot produce adequate hormone. This feedback loop explains why both hypothyroidism and hyperthyroidism can produce goiter through different mechanisms.

Goiters are classified as diffuse (uniform enlargement) or nodular (containing one or more discrete nodules). A multinodular goiter, common in older adults, often develops over decades. The American Thyroid Association (ATA) guidelines note that most goiters are asymptomatic and discovered incidentally during imaging or physical examination [2]. Symptoms arise when the gland compresses the trachea, esophagus, or recurrent laryngeal nerve, causing dysphagia, stridor, or voice changes.

Drug-induced goiter deserves special attention because it is both preventable and reversible in many cases. Several widely prescribed medications interfere with thyroid hormone synthesis or iodine metabolism, and clinicians should monitor thyroid function in patients taking these agents.

Drugs That Cause Goiter

Multiple prescription medications can enlarge the thyroid by blocking hormone synthesis, altering iodine handling, or triggering autoimmune thyroid inflammation. Recognizing these culprits early prevents misdiagnosis.

Lithium carbonate is the most well-documented goitrogen in clinical use. A meta-analysis published in The Journal of Clinical Endocrinology & Metabolism found that goiter develops in 40-50% of patients on long-term lithium therapy [3]. Lithium inhibits thyroid hormone release from the gland and reduces the conversion of T4 to the more active T3. It also promotes autoantibody formation. Patients on lithium require thyroid function testing every 6 to 12 months, per Endocrine Society recommendations [4].

Amiodarone, a class III antiarrhythmic, contains approximately 37% iodine by weight. A single 200 mg daily dose delivers roughly 75 mg of iodine, which is 500 times the recommended daily intake. Thyroid dysfunction occurs in 15-20% of amiodarone-treated patients [5]. Amiodarone-induced thyrotoxicosis (AIT) has two subtypes: type 1 (iodine-excess driven, often in patients with preexisting nodular goiter) and type 2 (destructive thyroiditis from direct drug toxicity). Both can produce or worsen goiter.

Other drug-induced goitrogens include:

• Interferon-alpha and interleukin-2: Used in hepatitis C and oncology regimens, these immunomodulators trigger autoimmune thyroiditis in 5-20% of patients, sometimes producing transient goiter [6].
• Tyrosine kinase inhibitors (sunitinib, sorafenib): These cancer drugs impair thyroid hormone synthesis and increase TSH. Hypothyroidism rates reach 36-85% depending on the agent and treatment duration [7].
• Ethionamide and para-aminosalicylic acid: Second-line tuberculosis drugs that directly inhibit thyroid peroxidase, the enzyme responsible for iodinating thyroglobulin.
• Iodine-containing contrast dyes: Rarely, repeated radiographic contrast exposure triggers the Wolff-Chaikoff effect (temporary iodine-induced hypothyroidism), which can produce goiter in susceptible individuals.

Dr. Elizabeth Pearce, an endocrinologist at Boston University School of Medicine, has noted: "Clinicians prescribing lithium or amiodarone should obtain baseline thyroid function tests and palpate the thyroid before initiating therapy, then monitor at regular intervals" [5].

Levothyroxine: The First-Line Medical Treatment

For nontoxic, diffuse, or mildly nodular goiter without hyperthyroidism, levothyroxine (T4) suppression therapy remains the primary pharmacologic option. The goal is to reduce TSH to low-normal levels (0.1-0.4 mIU/L), removing the growth stimulus on thyroid tissue.

A randomized controlled trial published in Annals of Internal Medicine demonstrated that levothyroxine reduced goiter volume by 20-25% over 12 months in patients with nontoxic diffuse goiter, compared with no significant change in placebo-treated controls [8]. Typical starting doses range from 50 to 100 mcg daily, titrated every 6 to 8 weeks based on TSH response.

The approach has limits. A Cochrane review of 10 trials (N=537) concluded that while levothyroxine does shrink nontoxic goiter, recurrence rates are high after discontinuation, and long-term TSH suppression carries risks of atrial fibrillation and accelerated bone loss, particularly in postmenopausal women [9]. The ATA recommends against levothyroxine suppression therapy in patients older than 60 or those with cardiac disease, low bone density, or autonomous thyroid nodules [2].

In younger patients with small diffuse goiters and mildly elevated TSH, the risk-benefit calculation favors treatment. Monitoring involves TSH measurement every 3 months during dose titration, then every 6 to 12 months once stable. Thyroid ultrasound at baseline and 12 months documents volumetric response.

Antithyroid Drugs for Toxic Goiter

When goiter is accompanied by hyperthyroidism (toxic multinodular goiter or Graves' disease), antithyroid drugs (ATDs) are a primary treatment option. These medications block thyroid peroxidase, reducing T3 and T4 production without destroying gland tissue.

Methimazole is preferred over propylthiouracil (PTU) in nearly all clinical scenarios. The ATA 2016 guidelines for hyperthyroidism recommend methimazole as first-line therapy due to its once-daily dosing, more consistent pharmacokinetics, and lower risk of severe hepatotoxicity [10]. Typical starting doses are 10-30 mg daily for moderate hyperthyroidism, tapered to 5-10 mg daily as maintenance.

PTU is reserved for two situations: the first trimester of pregnancy (methimazole is teratogenic during organogenesis) and thyroid storm. PTU carries an FDA black box warning for severe liver injury, including cases of liver failure and death [11].

Dr. David Cooper, professor of medicine at Johns Hopkins University School of Medicine and co-author of the ATA hyperthyroidism guidelines, has stated: "Methimazole should be used preferentially over propylthiouracil because of the rare but real risk of PTU-induced hepatotoxicity and the better dose-response predictability of methimazole" [10].

For toxic multinodular goiter specifically, ATDs rarely produce long-term remission. Unlike Graves' disease, where a 12-to-18-month course of methimazole achieves remission in 40-60% of patients, multinodular goiter typically recurs after ATD withdrawal. This makes ATDs a bridge therapy before definitive treatment with radioactive iodine or surgery in most multinodular goiter cases.

Agranulocytosis is the most feared ATD side effect, occurring in approximately 0.2-0.5% of patients [10]. Patients must be counseled to stop the medication and seek immediate medical attention if they develop fever, sore throat, or mouth ulcers.

Radioactive Iodine Therapy

Radioactive iodine (RAI, iodine-131) has been used to treat hyperthyroidism and reduce goiter volume since the 1940s. The thyroid avidly absorbs iodine, so orally administered I-131 concentrates in the gland and destroys follicular cells through beta radiation over weeks to months.

For toxic goiter with hyperthyroidism, a single RAI dose achieves euthyroidism in 80-90% of patients within 6 months [12]. For large nontoxic goiter causing compressive symptoms in patients who are poor surgical candidates, RAI offers a nonsurgical alternative. A prospective study from the Netherlands (N=150) published in the Journal of Clinical Endocrinology & Metabolism showed that RAI reduced goiter volume by a median of 40% at 12 months and 50-60% at 24 months [13].

Recombinant human TSH (rhTSH, Thyrogen) given before RAI can increase iodine uptake in nontoxic goiter, allowing lower radiation doses. A Danish randomized trial demonstrated that rhTSH-stimulated RAI achieved 35% greater volume reduction compared with RAI alone at one year [14].

The primary long-term consequence of RAI is hypothyroidism, which develops in the majority of treated patients and requires lifelong levothyroxine replacement. Transient radiation thyroiditis, causing neck pain and mild thyrotoxicosis, occurs in 1-5% of patients within the first two weeks. RAI is absolutely contraindicated in pregnancy and breastfeeding.

Surgery: When Drugs Are Not Enough

Thyroidectomy becomes necessary when medical and RAI options are inadequate or inappropriate. The ATA guidelines identify clear surgical indications: suspected or confirmed thyroid malignancy, large goiter causing significant compressive symptoms (tracheal deviation, dysphagia, stridor), substernal extension, coexistent hyperparathyroidism requiring neck exploration, or patient preference [15].

Total thyroidectomy is preferred over subtotal thyroidectomy for most goiter surgery. A long-term follow-up study published in World Journal of Surgery (N=5,000+) reported that subtotal thyroidectomy has a goiter recurrence rate of 15-40% over 10 to 30 years, compared with near-zero recurrence after total thyroidectomy [16]. The trade-off: total thyroidectomy commits the patient to lifelong thyroid hormone replacement and carries a slightly higher risk of permanent hypoparathyroidism (1-2%) and recurrent laryngeal nerve injury (0.5-1%).

Minimally invasive and robotic-assisted thyroidectomy techniques have expanded options for smaller goiters, though very large or substernal goiters still require conventional open approaches. Preoperative vocal cord assessment with laryngoscopy is standard practice. Patients with toxic goiter should be rendered euthyroid with methimazole before surgery to prevent thyroid storm during anesthesia induction.

Recovery after thyroidectomy typically involves 1 to 2 weeks of reduced activity. Calcium and vitamin D supplementation is routine in the immediate postoperative period because transient hypocalcemia from parathyroid gland manipulation affects 20-30% of patients after total thyroidectomy [15].

Iodine: Both Cause and Cure

Iodine occupies a paradoxical position in goiter pathophysiology. Too little causes goiter through chronic TSH stimulation. Too much can also cause goiter through the Wolff-Chaikoff effect or by triggering autoimmune thyroiditis in genetically predisposed individuals.

The WHO recommends 150 mcg of daily iodine intake for adults, with higher requirements during pregnancy (250 mcg) and lactation (250 mcg) [1]. Populations consuming below 50 mcg daily have endemic goiter rates exceeding 30%. Salt iodization programs, introduced in the 1920s in the United States and now implemented in over 120 countries, have dramatically reduced endemic goiter. Before universal salt iodization, the "goiter belt" across the Great Lakes and Pacific Northwest regions of the U.S. had goiter prevalence rates approaching 40%.

Potassium iodide (KI) supplementation at physiologic doses (150-250 mcg daily) treats iodine-deficiency goiter effectively. Higher pharmacologic doses (Lugol's solution, SSKI) are used short-term before thyroid surgery for Graves' disease to reduce gland vascularity and firmness, a technique described by Plummer in the 1920s.

Excess iodine from supplements, kelp products, or medications like amiodarone can worsen goiter in patients with underlying thyroid autonomy. This is known as the Jod-Basedow phenomenon and is particularly common when iodine-replete populations receive sudden large iodine loads [17].

Emerging Therapies and Combination Approaches

Several newer strategies are being evaluated for goiter management, particularly for patients who are not candidates for surgery or RAI.

Percutaneous ethanol injection (PEI) has shown efficacy for cystic thyroid nodules contributing to goiter. A meta-analysis in Thyroid (12 studies, N=641) reported complete cyst resolution in 72-93% of cases after 1 to 3 sessions [18]. PEI is less effective for solid nodules.

Radiofrequency ablation (RFA) and laser ablation are thermal techniques that reduce solid nodule volume by 50-80% over 12 months. The 2020 European Thyroid Association guidelines endorse RFA for benign, symptomatic, solid thyroid nodules in patients who decline or cannot undergo surgery [19]. These are outpatient procedures performed under local anesthesia with ultrasound guidance.

Combination therapy (low-dose RAI preceded by rhTSH) for large nontoxic goiter continues to gain traction. This approach allows effective volume reduction with lower radiation exposure to surrounding tissues, a meaningful consideration for patients with very large or partially substernal goiters.

Thyroid-targeted gene therapies and selective TSH receptor antagonists remain in preclinical stages. No novel pharmacologic agents specifically for goiter reduction have reached phase III trials as of 2026.

When to Seek Medical Evaluation

Any visible or palpable neck swelling warrants thyroid evaluation. Specific warning signs that require prompt assessment include rapid goiter growth over weeks (raising concern for thyroid lymphoma or anaplastic carcinoma), progressive dysphagia or breathing difficulty, hoarseness without an upper respiratory infection, and fixation of the mass to surrounding tissues.

The initial workup includes serum TSH, free T4, and thyroid peroxidase antibodies. If TSH is suppressed, a radioiodine uptake and scan differentiates Graves' disease from toxic multinodular goiter and subacute thyroiditis. Thyroid ultrasound characterizes nodule number, size, echogenicity, and suspicious features (microcalcifications, irregular margins, taller-than-wide shape). The ACR Thyroid Imaging Reporting and Data System (TI-RADS) scoring system guides fine-needle aspiration biopsy decisions based on nodule size and ultrasound features [20].

Fine-needle aspiration cytology, reported using the Bethesda System, determines whether nodules are benign, indeterminate, or malignant. Molecular testing (Afirma, ThyroSeq) refines risk stratification for indeterminate cytology results, potentially sparing patients from diagnostic surgery.

Patients taking lithium, amiodarone, or tyrosine kinase inhibitors should have thyroid palpation and TSH checked at baseline and every 6 months during treatment. A new goiter in a patient on one of these medications should prompt consideration of drug-related causation before pursuing aggressive intervention.